Sidmak Laboratories (India) Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 15-05-2024
- Paid Up Capital ₹ 1.81 Cr
as on 15-05-2024
- Company Age 41 YEARS, 4 MONTHS
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 Cr
as on 15-05-2024
- Satisfied Charges ₹ 8.52 Cr
as on 15-05-2024
- Revenue -13.02%
FY 2023
- Profit -261.45%
FY 2023
- Ebitda -74.60%
FY 2023
- Net Worth -4.26%
FY 2023
- Total Assets 3.24%
FY 2023
About Sidmak Laboratories (India)
The Corporate was formerly known as Sidmak Laboratories (India) Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 1.81 Cr.
The company currently has active open charges totaling ₹5.00 Cr. The company has closed loans amounting to ₹8.52 Cr, as per Ministry of Corporate Affairs (MCA) records.
Uday Shah, Vinayak Bhalani, and Dhananjay Desai serve as directors at the Company.
- CIN/LLPIN
U24230GJ1983PTC006157
- Company No.
006157
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 May 1983
- Date of AGM
29 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Valsad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sidmak Laboratories (India)?
Board Members(3)
Financial Performance and Corporate Structure Insights of Sidmak Laboratories (India).
Sidmak Laboratories (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.02% decrease. The company also saw a substantial fall in profitability, with a 261.45% decrease in profit. The company's net worth dipped by a decrease of 4.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sidmak Laboratories (India)?
In 2023, Sidmak Laboratories (India) had a promoter holding of 74.71% and a public holding of 25.29%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Gelnova Laboratories (India) Private Limited
Active
27 years 8 months Dhananjay Desai is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 17 Jan 2012 | ₹5.00 M | Open |
Axis Bank Limited Creation Date: 07 Jan 2004 | ₹4.50 Cr | Open |
Axis Bank Limited Creation Date: 08 Feb 2012 | ₹8.50 M | Satisfied |
How Many Employees Work at Sidmak Laboratories (India)?
Sidmak Laboratories (India) has a workforce of 402 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Apr 07, 2010, Sidmak Laboratories (India) has raised a total of ₹ 4.45 Cr, with the most recent deal valued at ₹ 4.45 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
